PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrom… Read more
PaxMedica, Inc. Common Stock (PXMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.327x
Based on the latest financial reports, PaxMedica, Inc. Common Stock (PXMD) has a cash flow conversion efficiency ratio of 0.327x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-632.32K) by net assets ($-1.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PaxMedica, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how PaxMedica, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PaxMedica, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PaxMedica, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CANFOR PULP (8CP.SG)
STU:8CP
|
0.182x |
|
Remala Abadi Tbk.
JK:DATA
|
0.105x |
|
COMA 18 JSC
VN:CIG
|
N/A |
|
PRIMAG (P9R.SG)
STU:P9R
|
N/A |
|
Sidney Resources Corp
PINK:SDRC
|
-0.113x |
|
Orkim Berhad
KLSE:5348
|
N/A |
|
CARBACID INVESTMENTS LTD
XNAI:CIL
|
N/A |
|
ESGold Corp.
OTCQB:ESAUF
|
-0.074x |
Annual Cash Flow Conversion Efficiency for PaxMedica, Inc. Common Stock (2018–2023)
The table below shows the annual cash flow conversion efficiency of PaxMedica, Inc. Common Stock from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.39 Million | $-10.77 Million | -3.181x | +94.30% |
| 2022-12-31 | $108.80K | $-6.07 Million | -55.801x | -10332.63% |
| 2021-12-31 | $-10.11 Million | $-5.51 Million | 0.545x | +7.46% |
| 2020-12-31 | $-4.63 Million | $-2.35 Million | 0.507x | -88.11% |
| 2019-12-31 | $-98.30K | $-419.38K | 4.266x | +104.15% |
| 2018-12-31 | $2.72K | $-279.87K | -102.855x | -- |